^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE10 inhibitor

    Related drugs:
    11d
    Allevia2: Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome (clinicaltrials.gov)
    P2, N=164, Active, not recruiting, Noema Pharma AG | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    Allevia2: Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome (clinicaltrials.gov)
    P2, N=180, Recruiting, Noema Pharma AG | Trial completion date: Dec 2026 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Feb 2026
    Trial completion date • Trial primary completion date
    3ms
    COMBAT-ALS: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS (clinicaltrials.gov)
    P2/3, N=234, Active, not recruiting, MediciNova | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eyevinal (ibudilast)
    4ms
    RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (clinicaltrials.gov)
    P2/3, N=460, Suspended, University Health Network, Toronto | Trial completion date: Mar 2025 --> Dec 2025 | Active, not recruiting --> Suspended
    Trial completion date • Trial suspension
    |
    Eyevinal (ibudilast)
    5ms
    Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (clinicaltrials.gov)
    P2, N=120, Recruiting, VA Office of Research and Development | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Eyevinal (ibudilast)
    7ms
    MN-166-GBM-1201: Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=64, Completed, MediciNova | Active, not recruiting --> Completed
    Trial completion
    |
    temozolomide • Eyevinal (ibudilast)
    7ms
    Ibudilast for Treating Alcohol Use Disorder (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> Dec 2027 | Trial primary completion date: Dec 2027 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Eyevinal (ibudilast)
    10ms
    RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (clinicaltrials.gov)
    P2/3, N=460, Active, not recruiting, University Health Network, Toronto | Suspended --> Active, not recruiting | Trial completion date: Dec 2026 --> Mar 2025 | Trial primary completion date: May 2026 --> Mar 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Eyevinal (ibudilast)
    10ms
    Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia (clinicaltrials.gov)
    P2, N=104, Completed, Celon Pharma SA | Recruiting --> Completed
    Trial completion
    11ms
    RECLAIM: Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine (clinicaltrials.gov)
    P2/3, N=460, Suspended, University Health Network, Toronto | N=1000 --> 460 | Recruiting --> Suspended
    Enrollment change • Trial suspension
    |
    Eyevinal (ibudilast)
    11ms
    Inhalable Carbonyl Sulfide Donor-Hybridized Selective Phosphodiesterase 10A Inhibitor for Treating Idiopathic Pulmonary Fibrosis by Inhibiting Tumor Growth Factor-β Signaling and Activating the cAMP/Protein Kinase A/cAMP Response Element-Binding Protein (CREB)/p53 Axis. (PubMed, ACS Pharmacol Transl Sci)
    A dry powder inhalation formulation called COS-2080-DPI has been developed using the ultrasonic spray freeze drying (USFD) technique, demonstrating significant antifibrotic efficacy in mice with bleomycin-induced PF at a dosage approximately 600 times lower than pirfenidone. Moreover, COS-2080 effectively attenuated fibrosis in MRC-5 cells by activating the cAMP/protein kinase A (PKA)/CREB pathway and potentially increasing levels of p53 protein. Our findings suggest that effective inhibition of PDE10A potentially confers a protective effect on FMT in PF by impeding TGF-β signaling and activating the cAMP/PKA/CREB/p53 axis.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • SMAD2 (SMAD Family Member 2) • SMAD3 (SMAD Family Member 3)
    |
    bleomycin
    12ms
    SEANOBI-ALS: Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS (clinicaltrials.gov)
    P=N/A, N=0, Available, Mayo Clinic
    New trial
    |
    Eyevinal (ibudilast)